6-CL-ADBA
€ 49,95
6-CL-ADBA Powder is described as a laboratory research material associated with a chlorinated indazole carboxamide analog featuring an N-adamantyl-substituted scaffold. Raw Lab Chems identifies this material exclusively for controlled chemical identification, chromatographic characterization, mass-spectrometric investigation, and analytical method development. The supplied chemical identifiers and claims concerning purity, batch traceability, independent testing, and specialized packaging require supporting documentation before they can be considered verified.
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.
6-CL-ADBA Powder 1g – Chlorinated Indazole Research Material
Product Overview
6-CL-ADBA Powder is described in the supplied information as a laboratory research material associated with a chlorinated synthetic indazole carboxamide analog.
The source identifies the compound by the abbreviation 6-CL-ADBA and the alternative name 6-Chloro-ADB-A.
Its proposed chemical classification provides a basis for analytical investigations involving molecular identification, structural comparison, chromatographic behavior, and spectroscopic characterization.
Raw Lab Chems presents the material exclusively within a Research Use Only framework.
The supplied source describes an off-white to light beige crystalline powder intended for controlled laboratory examination.
However, the stated physical presentation does not independently establish the actual chemical identity, purity, crystalline structure, or composition of the material.
The source also characterizes the preparation as laboratory-grade and refers to independent analytical verification and controlled manufacturing conditions.
These descriptions remain supplier-provided claims until supported by documentation associated with the actual batch.
No clinical, therapeutic, diagnostic, dietary, or consumer-oriented application is represented by this description.
Chemical Identity & Classification
6-CL-ADBA is identified in the supplied information as a chlorinated indazole carboxamide derivative.
The source also describes an N-adamantyl-substituted scaffold and uses the alternative designation 6-Chloro-ADB-A.
The supplied chemical-reference information is:
- Product designation: 6-CL-ADBA
- Alternative name: 6-Chloro-ADB-A
- Proposed classification: Chlorinated indazole carboxamide derivative
- Reported structural feature: N-Adamantyl substitution
- Reported molecular formula: C18H26ClN4O2
- Reported molecular weight: 378.89 g/mol
- CAS Registry Number: Not supplied
These details are reproduced from the source and should not be treated as independently verified chemical identifiers.
An important identity discrepancy requires resolution: the supplied molecular formula and molecular weight do not appear mutually consistent. The reported formula C18H26ClN4O2 corresponds to an approximate formula mass of 365.86 g/mol, not 378.89 g/mol.
The source also does not provide a complete systematic chemical name, verified structure, stereochemical specification, or confirmed salt form.
Consequently, the exact chemical identity should remain provisional until the structural information and molecular data are reconciled through authoritative documentation.
The source states that no CAS Registry Number has been assigned, but this assertion has not been independently verified.
Researchers seeking public chemical-reference information may consult PubChem, ensuring that any selected record corresponds to a verified chemical structure rather than relying solely on a product abbreviation.
Chemical & Physical Characteristics
The supplied product is described as an off-white to light beige crystalline powder.
No product-specific physical inspection record, microscopy report, diffraction dataset, or other evidence was provided to establish its actual appearance or crystalline state.
The stated physical form therefore remains a source-provided description.
The proposed indazole carboxamide classification provides a preliminary framework for comparison with related synthetic compounds.
However, structural similarity does not establish identical physical properties, analytical behavior, stability, or impurity profiles.
The source references solubility and stability under analytical conditions as research topics.
No verified melting point, quantitative solubility profile, particle-size distribution, crystalline polymorph, density, or hygroscopicity measurement was supplied.
These characteristics should not be inferred from the compound abbreviation or proposed chemical family.
The source recommends freezer storage at −20°C with protection from light and moisture.
No validated stability study, degradation profile, or experimentally established shelf-life specification accompanied this recommendation.
Researchers should distinguish general storage guidance from verified stability data associated with a particular batch.
Purity & Analytical Verification
The supplied description claims purity of at least 98%, characterized as typical and determined by HPLC.
However, no actual batch-specific Certificate of Analysis, chromatogram, mass spectrum, NMR spectrum, or independent laboratory report was provided.
Accordingly, the stated purity threshold is not independently confirmed for the material described here.
The source identifies HPLC, mass spectrometry, NMR spectroscopy, and LC-MS/MS as analytical techniques associated with the investigation of related synthetic compounds.
Such methods may provide information concerning chemical identity, structural characteristics, impurity profiles, and analytical specificity.
However, naming an analytical technique does not establish that it was performed on the actual product.
The unresolved discrepancy between the supplied molecular formula and molecular weight makes independent chemical identification particularly important.
The source also references positive-ion mass spectrometry, fragmentation patterns, and analytical method development as research topics.
These references describe possible analytical investigation areas rather than validated performance characteristics of the supplied material.
Any reported purity or identity result should be evaluated against the actual sample, method documentation, reference materials, and relevant analytical limitations.
No certified reference-material status or independently established purity specification is asserted.
Quality Control & Batch Integrity
The supplied source claims that individual batches undergo third-party testing and are supported by Certificates of Analysis.
It also describes batch traceability, verification of identity and purity, and testing for residual solvents and homogeneity.
No actual certificate, laboratory accreditation record, manufacturing audit, quality-system documentation, or batch-specific testing report accompanied these statements.
They therefore remain unverified supplier claims.
For reproducible laboratory investigation, useful documentation may include supplier identification, batch number, chemical identifier, receipt date, storage history, and available analytical findings.
Where a material is described as suitable for reference-standard work, researchers should distinguish ordinary catalog material from a certified reference material.
The supplied information does not establish certified reference-material status, metrological traceability, or an assigned measurement uncertainty.
Likewise, the description does not independently demonstrate compliance with a particular quality-management certification.
Claims of consistent purity, identity, homogeneity, or manufacturing quality should be supported by actual analytical records rather than inferred from catalog terminology.
Safety, Handling & Laboratory Precautions
6-CL-ADBA is described as a synthetic indazole carboxamide derivative requiring appropriate institutional risk assessment and controlled laboratory handling.
Research personnel should consult applicable chemical-safety documentation and institutional procedures before receiving or examining the material.
Laboratory precautions should address access restrictions, protective equipment, contamination prevention, accidental exposure, environmental release, and chemical-waste disposal.
The proposed structural relationship to other synthetic indazole derivatives does not establish safety for human or veterinary exposure.
The material should remain secured against unauthorized access and separated from food, beverages, and non-research environments.
Because the actual chemical identity, purity, and chemical form have not been independently confirmed, laboratory documentation should distinguish verified characteristics from supplier-provided statements.
The powder presentation must not be interpreted as evidence of pharmaceutical suitability or authorization for personal use.
Packaging, Labeling & Storage
The supplied source describes resealable inert packaging, thermal protection, appropriate chemical labeling, and professional handling during transportation.
No packaging-validation study, verified container specification, or actual shipment-condition record accompanied these claims.
The source recommends storage at −20°C in a desiccated environment protected from light and moisture.
No validated stability data was provided to establish that this temperature is necessary or sufficient for a particular shelf life.
The source additionally claims that packaging and transportation arrangements meet IATA and DOT requirements.
No shipment classification, carrier documentation, or compliance record was supplied to substantiate those statements.
Laboratory inventory records should preserve the compound designation, any available batch identifier, receipt details, and relevant storage observations.
The unresolved molecular identity information should also be recorded rather than replaced with an assumed specification.
Packaging and environmental requirements should be assessed using available safety documentation, relevant stability evidence, and institutional laboratory procedures.
Intended Research Use & Market Positioning
The supplied scientific context places 6-CL-ADBA within analytical research involving chlorinated indazole derivatives, chemical characterization, structural comparison, and forensic identification.
Its proposed scaffold provides a basis for comparing chemical-reference information associated with related synthetic compounds.
The source also references chromatographic separation, mass-spectrometric fragmentation, and spectroscopic characterization as areas of laboratory investigation.
These references describe analytical research contexts and do not establish any human-use application.
For comparative chemical-catalog research, Raw Lab Chems also lists ADB-BUTINACA and 5Br-ADB-INACA Powder.
These listings identify other named synthetic indazole-related research materials but do not establish equivalent chemical identity, purity, formulation, or analytical characteristics.
The supplied 6-CL-ADBA catalog reference identifies the product presentation discussed here.
These references provide chemical-catalog context rather than evidence of certified reference-material status or interchangeability.
Ordering, Availability & Fulfillment
The supplied source describes worldwide shipping, discreet packaging, tracking, thermal protection, and transportation through compliant carriers.
No current inventory information, carrier record, destination-specific authorization, or verified shipment-performance documentation was provided.
Consequently, no specific availability, delivery, customs-clearance, transportation-compliance, or temperature-control guarantee is asserted.
Synthetic indazole carboxamide derivatives may be subject to controlled-substance, synthetic cannabinoid, or analog legislation.
Institutional acquisition and transfer should therefore be assessed against the applicable laws governing the exact substance and chemical form involved.
Researchers and institutions should independently verify whether possession, importation, exportation, transportation, and laboratory investigation are authorized in their jurisdictions.
Research-only labeling does not establish an exemption from controlled-substance regulations.
Legal & Regulatory Disclaimer
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.
6-CL-ADBA is described as a chlorinated indazole carboxamide analog whose exact chemical identity and legal classification require verification.
Acquisition, possession, transfer, importation, exportation, storage, and laboratory investigation may be restricted or prohibited under applicable controlled-substance, analog, synthetic cannabinoid, or other chemical regulations.
Researchers and institutions remain responsible for determining legal requirements and obtaining any necessary authorizations.
No medical approval, consumer-use authorization, universal legal status, or regulatory exemption is implied by this description.
You must be logged in to post a review.

Reviews
There are no reviews yet.